An initial report of a phase-III trial comparing vindesine and vincristine for acute lymphocytic leukemia of childhood.
The initial results from the Children's Cancer Study Group (CCSG) study on vindesine are the subject of this report. Vindesine was shown to be active in the treatment of acute lymphocytic leukemia (ALL) in children in a phase-II clinical trial conducted by the CCSG. A phase-II trial is now in progress. The aim of this is to compare the use of vincristine and of vindesine with reference to induction rate, toxicity, and cross-resistance.
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004351:Drug Resistance; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D014747:Vinblastine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use*
D014750:Vincristine; D014747:Vinblastine